人ProIGF-I EB（104 - 123）抗血清是通过用衍生自与白喉类毒素连接的人ProIGF-I EB的21个氨基酸的肽免疫兔来制备的。 该肽位于195个氨基酸的ProIGF-I EB的E结构域内，其来源于人igf-1基因的选择性剪接。 抗血清识别ProIGF-I EB，但不识别ProIGF-I EA、ProIGF-I EC、成熟IGF-I或IGF-II。 肽序列分析表明，由于igf-1基因的选择性剪接，它可以识别多种非人灵长类动物中的ProIGF-I EB相关蛋白，但不能识别许多其它物种。 与牛、猪和犬种中ProIGF-I变体的相似区域有显着的同源性，提示其可能有效。 Human ProIGF-I EB (104-123) antiserum was prepared by immunising rabbits with a 21 amino acid peptide derived from human ProIGF-I EB linked to diphtheria toxoid. The peptide is located within the E domain of the 195 amino acid ProIGF-I EB, derived from alternative splicing of the human igf-1 gene. The antiserum recognises ProIGF-I EB but not ProIGF-I EA, ProIGF-I EC, mature IGF-I or IGF-II. Peptide sequence analysis suggest it may recognise ProIGF-I EB related proteins in a range of non-human primates but not many other species due to alternative splicing of the igf-1 gene. There is significant homology to similar regions of ProIGF-I variants in bovine, porcine and canine species to suggest it may be effective.
GroPep Bioreagents公司总部位于澳大利亚，成立于1990年，致力于向广大科研院所、生物技术及制药公司开发、生产和销售细胞培养级的活性生长因子（主要集中在胰岛素样生长因子（IGF）领域）、抗体及相关蛋白试剂，现有产品超过100多个，同时在世界范围内均设有分销商。公司在分子生物领域、发酵学及重组蛋白和单抗制备方面具有丰富的经验，在制造工艺方面，拥有大量专利技术，GroPep目前已通过AS/NZS ISO 9001:2016质量管理体系认证。
